The research you fund through LCRF is making meaningful progress in the fight against lung cancer. We are pleased to share our 2023 grantees’ one-year updates in this series.
Carl Gay, MD, PhD
MD Anderson Cancer Center
2023 LCRF–Daiichi Sankyo–AstraZeneca Research Grant on Antibody Drug Conjugates
What he’s doing:
Dr. Gay is evaluating targeted therapies for small cell lung carcinoma (SCLC) and large cell neuroendocrine lung cancer—both of which remain difficult to treat. His research focuses on two biomarkers, HER2 and TROP2, which are expressed in these aggressive cancers. Dr. Gay’s team is evaluating antibody-drug conjugates (ADCs), a promising treatment approach that uses antibodies to deliver chemotherapy directly to cancer cells.
What it could mean for patients:
ADCs targeting HER2 and TROP2 are already in use for other cancers, and Dr. Gay is testing whether these existing therapies could offer a much-needed new option for patients with high-grade neuroendocrine lung cancers.
